Qualitative study | Validation study | ||||||||
---|---|---|---|---|---|---|---|---|---|
Characteristics | Health conditions | Health conditions | |||||||
Crohn’s disease | Diabetes mellitus type 1 | Healthy | Rheumatoid arthritis | Systemic lupus erythematosus | Systemic sclerosis | Healthy | Rheumatoid arthritis | Systemic lupus erythematosus | |
n participants | 15 | 15 | 15 | 15 | 15 | 15 | 76 | 132 | 43 |
n (%) | |||||||||
Female | 8 (53) | 8 (53) | 10 (67) | 11 (73) | 9 (53) | 11 (73) | 48 (63) | 116 (88) | 41 (95) |
Employed+ | 8 (53) | 8 (53) | 11 (73) | 0 | 10 (67) | 4 (27) | 65 (86) | 42 (32) | 21 (49) |
β-Blocker/ACE inhibitors/statins | 1(7) | 6 (40) | -- | 3 (20) | 9 (60) | 9 (60) | -- | 43 (35) | 17 (46) |
DMARD | 7 (47) | -- | -- | 15 (100) | 9 (60) | 2 (13) | -- | 70 (54) | 32 (76) |
Biologic | 5 (33) | -- | -- | 8 (47) | 0 | 0 | -- | 54 (42) | 0 |
ASA | 9 (60) | -- | -- | -- | -- | -- | -- | -- | -- |
Cortisone | -- | -- | -- | 5 (33) | 10 (67) | 4 (27) | -- | 47 (36) | 26 (63) |
Low disease activity/remission | 11 (73)a | 3 (27)b | -- | 7 (47)c | 1 (7)d | 10(67)e | -- | 96 (72)c | 36 (83)e |
Median (IQR) | |||||||||
Age | 46 | 53 | 36 | 54 | 46 | 67 | 38 | 59 | 46 |
(34-60) | (36-63) | (32-62) | (43-58) | (32-60) | (50-74) | (27-49) | (48-65) | (36-53) | |
Disease duration | 15 | 20 | -- | 11 | 10 | 10 | -- | 10 | 10 |
(8-30) | (11-40) | (9-20) | (8-19) | (4-16) | (4-16) | (8-17) |